Abstract:Nasopharyngeal carcinoma (NPC) has seen improved treatment outcomes and a decrease in incidence worldwide in recent years due to developments in medicine and improved public health. However, 70% of cases are still diagnosed at advanced stages and these advanced NPC cases show a poor prognosis. Reports on current and future treatment in advanced NPC are summarized. Chemoradiotherapy is the mainstay of treatment for advanced NPC. The administration of platinum agents as a concurrent drug and intensity modulated radiotherapy (IMRT) is the most appropriate irradiation method, and is associated with high local control rates. For induction and adjuvant chemotherapy, platinum-based two- or three-drug combination chemotherapy is recommended. The tumour volume, plasma Epstein-Barr virus (EBV)-DNA levels, and the tumour site are used to determine the indication for adjuvant and neo-adjuvant chemotherapy. The tolerability of induction chemotherapy is controversial, and the indications and timing should be carefully considered in each case. Chemotherapy is used for patients with distant metastasis. Gemcitabine/cisplatin is the first-line regimen. The efficacy of immune checkpoint inhibitor (ICI) treatment has recently been reported for NPC and, as in other areas of the head and neck, it is expected to be effective for patients with recurrent/distant metastasis. Trials are underway for various uses of ICIs, including induction chemotherapy, postoperative treatment, and use in combination with chemoradiotherapy. Immunotherapy for NPC, an EBV-associated cancer, has been reported to have some efficacy with immunotherapy used in other EBV-associated cancers. Immunotherapy may be introduced for NPC in the future, depending on the results of clinical trials. Future changes in the treatment of NPC are expected to include risk classification based on plasma EBV-DNA levels and the development of personalized treatment with individual selection of timing and type of therapy.

Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies

Novel therapy for nasopharyngeal carcinoma--where are we

Nasopharyngeal carcinoma: an evolving paradigm

Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma.

Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma

Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)

Precision Medicine for Nasopharyngeal Cancer—A Review of Current Prognostic Strategies

Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer

Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?

Advances in Pathogenesis and Precision Medicine for Nasopharyngeal Carcinoma

Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

Cancer Stem-Like Cell: A Novel Target for Nasopharyngeal Carcinoma Therapy

Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options

Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.

Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma

Novel systemic therapeutic for nasopharyngeal carcinoma

Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma

Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options

Clinical Trials in Nasopharyngeal Carcinoma—past, Present and Future